Detalhe da pesquisa
1.
Evaluation of the tolerability and safety of [225Ac]Ac-PSMA-I&T in patients with metastatic prostate cancer: a phase I dose escalation study.
BMC Cancer
; 24(1): 146, 2024 Jan 29.
Artigo
Inglês
| MEDLINE | ID: mdl-38287346
2.
Urinary excretion kinetics of [177Lu]Lu-PSMA-617.
Eur J Nucl Med Mol Imaging
; 50(12): 3572-3575, 2023 10.
Artigo
Inglês
| MEDLINE | ID: mdl-37421427
3.
Efficacy and safety of peptide receptor radionuclide therapy with [177Lu]Lu-DOTA-TATE in 15 patients with progressive treatment-refractory meningioma.
Eur J Nucl Med Mol Imaging
; 50(4): 1195-1204, 2023 03.
Artigo
Inglês
| MEDLINE | ID: mdl-36454268
4.
[111In]In-CP04 as a novel cholecystokinin-2 receptor ligand with theranostic potential in patients with progressive or metastatic medullary thyroid cancer: final results of a GRAN-T-MTC Phase I clinical trial.
Eur J Nucl Med Mol Imaging
; 50(3): 892-907, 2023 02.
Artigo
Inglês
| MEDLINE | ID: mdl-36334104
5.
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT).
Eur J Nucl Med Mol Imaging
; 50(9): 2830-2845, 2023 07.
Artigo
Inglês
| MEDLINE | ID: mdl-37246997
6.
New Radiolabeled Exendin Analogues Show Reduced Renal Retention.
Mol Pharm
; 20(7): 3519-3528, 2023 07 03.
Artigo
Inglês
| MEDLINE | ID: mdl-37265006
7.
Exploring the translational challenge for medical applications of ionising radiation and corresponding radiation protection research.
J Transl Med
; 20(1): 137, 2022 03 18.
Artigo
Inglês
| MEDLINE | ID: mdl-35303930
8.
In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T.
Eur J Nucl Med Mol Imaging
; 49(11): 3627-3638, 2022 09.
Artigo
Inglês
| MEDLINE | ID: mdl-35556158
9.
EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands.
Eur J Nucl Med Mol Imaging
; 49(6): 1778-1809, 2022 05.
Artigo
Inglês
| MEDLINE | ID: mdl-35284969
10.
Intra-therapeutic dosimetry of [177Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome.
Eur J Nucl Med Mol Imaging
; 49(2): 460-469, 2022 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34218300
11.
Intraprocedural MRI-based dosimetry during transarterial radioembolization of liver tumours with holmium-166 microspheres (EMERITUS-1): a phase I trial towards adaptive, image-controlled treatment delivery.
Eur J Nucl Med Mol Imaging
; 49(13): 4705-4715, 2022 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-35829749
12.
Safety of [177Lu]Lu-NeoB treatment: a preclinical study characterizing absorbed dose and acute, early, and late organ toxicity.
Eur J Nucl Med Mol Imaging
; 49(13): 4440-4451, 2022 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-35951084
13.
[68Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [177Lu]Lu-PSMA-617 treatment.
Eur J Nucl Med Mol Imaging
; 49(4): 1101-1112, 2022 03.
Artigo
Inglês
| MEDLINE | ID: mdl-34623453
14.
89Zr-labeled PSMA ligands for pharmacokinetic PET imaging and dosimetry of PSMA-617 and PSMA-I&T: a preclinical evaluation and first in man.
Eur J Nucl Med Mol Imaging
; 49(6): 2064-2076, 2022 05.
Artigo
Inglês
| MEDLINE | ID: mdl-34932154
15.
EANM position paper on article 56 of the Council Directive 2013/59/Euratom (basic safety standards) for nuclear medicine therapy.
Eur J Nucl Med Mol Imaging
; 48(1): 67-72, 2021 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33057773
16.
EANM position paper on the role of radiobiology in nuclear medicine.
Eur J Nucl Med Mol Imaging
; 48(11): 3365-3377, 2021 10.
Artigo
Inglês
| MEDLINE | ID: mdl-33912987
17.
Phase I study to assess safety, biodistribution and radiation dosimetry for 89Zr-girentuximab in patients with renal cell carcinoma.
Eur J Nucl Med Mol Imaging
; 48(10): 3277-3285, 2021 09.
Artigo
Inglês
| MEDLINE | ID: mdl-33651116
18.
To 1000 Gy and back again: a systematic review on dose-response evaluation in selective internal radiation therapy for primary and secondary liver cancer.
Eur J Nucl Med Mol Imaging
; 48(12): 3776-3790, 2021 11.
Artigo
Inglês
| MEDLINE | ID: mdl-33839892
19.
Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy.
Eur J Nucl Med Mol Imaging
; 48(5): 1339-1350, 2021 05.
Artigo
Inglês
| MEDLINE | ID: mdl-33094433
20.
Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist 177 Lu-DOTAGA-PEG2 -RM26.
Int J Cancer
; 145(12): 3347-3358, 2019 12 15.
Artigo
Inglês
| MEDLINE | ID: mdl-31077356